HER2-negative Breast Cancer
Showing 1 - 25 of 91
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer Trial (BGB-43395, Fulvestrant, Letrozole)
Not yet recruiting
- Advanced Solid Tumor
- +8 more
- BGB-43395
- +2 more
- (no location specified)
Nov 13, 2023
HER2-negative Breast Cancer, Advanced Breast Cancer Trial in Guangzhou (Organoid-guided treatment, Taxane, Capecitabine)
Not yet recruiting
- HER2-negative Breast Cancer
- Advanced Breast Cancer
- Organoid-guided treatment
- +5 more
-
Guangzhou, Guangdong, ChinaGuangdong Provincial People's Hospital
Oct 22, 2023
Clinical Outcomes in HR+ and HER2-low/Negative Breast Cancer
Active, not recruiting
- Hormone-receptor-positive Breast Cancer
- +2 more
- No drug
-
Cambridge, MassachusettsConcertAI database
Sep 8, 2023
Breast Cancer, Hyperinsulinism, HER2-negative Breast Cancer Trial in New Haven (Dapagliflozin 10mg)
Not yet recruiting
- Breast Cancer
- +2 more
- Dapagliflozin 10mg
-
New Haven, ConnecticutYale Cancer Center Smilow Cancer Hospital
Aug 3, 2023
Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor Trial (Elacestrant, Triptorelin)
Not yet recruiting
- Breast Cancer
- +3 more
- (no location specified)
Aug 4, 2023
HER2-negative Breast Cancer Trial in Budapest (device, drug, procedure)
Recruiting
- HER2-negative Breast Cancer
- Oncotherm EHY-2030
- +4 more
-
Budapest, HungaryDivision of Oncology, Department of Internal Medicine and Oncolo
May 25, 2023
CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective
Recruiting
- Breast Cancer
- +2 more
-
Erlangen, GermanyDepartment of Gynecology and Obstetrics, Erlangen University Hos
May 12, 2023
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer Trial in Chicago, Minneapolis (ALX148, Fam-Trastuzumab
Recruiting
- HER2-positive Breast Cancer
- +17 more
- ALX148
- Fam-Trastuzumab Deruxtecan-Nxki
-
Chicago, Illinois
- +1 more
May 19, 2023
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer Trial in Miami (AI+CDK4/6i, SERD+CDK4/6i, mTOR inhibitor +
Not yet recruiting
- Breast Cancer
- +3 more
- AI+CDK4/6i
- +7 more
-
Miami, FloridaUniversity of Miami
Apr 12, 2023
HER2-negative Breast Cancer, Metastatic Breast Cancer, Metaplastic Breast Carcinoma Trial in Houston (L-NMMA)
Recruiting
- HER2-negative Breast Cancer
- +3 more
-
Houston, TexasHouston Methodist Neal Cancer Center
Jan 12, 2023
Triple Negative Breast Cancer, HER2-negative Breast Cancer Trial in Tampa (HER2 - primed Dendritic cells, HER3 - primed
Recruiting
- Triple Negative Breast Cancer
- HER2-negative Breast Cancer
- HER2 - primed Dendritic cells
- HER3 - primed Dendritic cells
-
Tampa, FloridaMoffitt Cancer Center
Jan 10, 2023
Breast Tumor, Breast Cancer, Hormone Receptor Positive Tumor Trial in Shanghai (PIK3CA inhibitor, AKT inhibitor, Carrelizumab)
Recruiting
- Breast Neoplasm
- +4 more
- PIK3CA inhibitor
- +12 more
-
Shanghai, Shanghai, ChinaBreast cancer institute of Fudan University Cancer Hospital
Jan 2, 2023
Breast Cancer, Estrogen Receptor Positive Tumor, HER2-negative Breast Cancer Trial in Seoul (Ovarian function suppression with
Not yet recruiting
- Breast Cancer
- +4 more
- Ovarian function suppression with endocrine treatments
-
Seoul, Korea, Korea, Republic ofGangnam Severance Hospital
Dec 18, 2022
Pancreatic Adenocarcinoma Metastatic, BRCA1 Mutation, BRCA2 Mutation Trial in Boston, New York (Melphalan, BCNU, Vitamin B12B)
Recruiting
- Pancreatic Adenocarcinoma Metastatic
- +14 more
- Melphalan
- +5 more
-
Boston, Massachusetts
- +1 more
Dec 6, 2022
Breast Tumors, Breast Cancer, Breast Tumors Trial in United States (Standard Therapy, AMG 386 with or without Trastuzumab, AMG
Recruiting
- Breast Neoplasms
- +10 more
- Standard Therapy
- +32 more
-
Birmingham, Alabama
- +35 more
Nov 17, 2022
Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Alpelisib, Tamoxifen, Infigratinib)
Not yet recruiting
- Breast Cancer
- +2 more
- Alpelisib
- +3 more
-
Stanford, CaliforniaStanford University
Nov 16, 2022
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer Trial in United States (Pembrolizumab, Sacituzumab
Recruiting
- Invasive Breast Cancer
- +3 more
- Pembrolizumab
- Sacituzumab Govitecan
-
Atlanta, Georgia
- +7 more
Nov 14, 2022
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer Trial in United States (Niraparib, Dostarlimab)
Recruiting
- Stage I Breast Cancer
- +7 more
-
Baltimore, Maryland
- +6 more
Nov 11, 2022
HER2-negative Breast Cancer, Triple Negative Breast Cancer Trial in France, Germany, Ireland (Capecitabine, Carboplatin,
Recruiting
- HER2-negative Breast Cancer
- Triple Negative Breast Cancer
- Capecitabine
- +3 more
-
Brasschaat, Belgium
- +161 more
Nov 2, 2022